Key result
Permanent pacing for syncope prevention is associated with appreciable recurrence rates, highlighting the need to correlate bradyarrhythmia with syncope before device implantation.
Answers are grounded in this paper and cite their sources.
Recurrent syncope remains a significant issue in patients paced for reflex syncope, necessitating strict adherence to guideline-directed patient selection and reduction of hypotensive medications.
This editorial refers to ‘Risk of syncopal recurrences in patients treated with permanent pacing for bradyarrhythmic syncope: role of correlation between symptoms and ECG findings’ by P. Palmisano et al., on pages 1729--1736. The question of recurrent syncope in patients who are paced for syncope prevention is one that has received far less attention in the literature than it deserves. The first paper of value in the field was Langenfeld et al.,1 which addressed patients with clear pacing indications, mainly atrioventricular block, finding low recurrence rates of 5% in 3 years. There followed a report of the DANPACE group showing higher rates, 16% in 3 years, in patients paced dual chamber for sinoatrial node disease.2 More recently, the Lavagna group confirmed low recurrence rates in a larger series with longer follow-up of atrioventricular block.3 The Syncope Unit Project (SUP) 24 looked in detail at recurrent syncope in older patients with likely reflex syncope in a real-world setting. Those with carotid sinus syndrome had less syncope recurrence, while the reflex syncope group with dominant cardioinhibition (tilt positive) and those with implantable loop recorders (ILR)-documented asystole fared worse over an actuarial 3-year analysis: 16% vs. 23% and 24%, respectively.4 Yasa et al.5 showed that recurrent syncope in paced patients was most frequently due to autonomic nervous system disorders when thorough investigation of cause was undertaken. The study presented in this issue of Europace by Palmisano et al.6 focuses on syncope recurrence in a broad group of patients with syncope who were paced. The strength of the study is that it was multicentre, real-world covering all aetiologies requiring pacing and with a large sample. For this, the authors are to be congratulated. There were, however, weaknesses with their Group C being largely undiagnosed syncope in generally frail patients, incomplete use of ILR, follow-up was also incomplete and there were no available details of the pacemakers and their programmes. Besides, it is important to emphasize, that the protocol was not truly prospective as the protocol was designed only recently while it retrieved the follow-up data of patients implanted in the years 2010–2013. The context of pacemaker selection to achieve optimal results including reduction of recurrent syncope to a minimum was addressed in the 2013 European Society of Cardiology (ESC) Guidelines on cardiac pacing and cardiac resynchronization therapy7 and the ESC Guidelines on Syncope8 although the latter were unavailable at the beginning of the Palmisano study.6 The Guidelines7 recommended that patients should be approached on the basis of their clinical presentation, rather than that advised in the past, the aetiology of their bradyarrhythmia (Figure 1). This figure shows much overlap with that of the Palmisano group6 except, perhaps, in use of ILRs in the electrocardiogram documented group where greater use was anticipated in the Guidelines. In this respect, the study of Palmisano et al. has validated, in daily practice, the clinical presentation approach suggested by ESC guidelines.8 A flow diagram for management of patients being considered for anti-bradyarrhythmia pacing based on the patient’s clinical presentation. Modified from: 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.7 AV, atrioventricular; BBB, bilateral bundle branch block; parox, paroxysmal; PM, pacemaker; SSS, sinoatrial node disease. This shows the currently anticipated rate of syncope recurrence in patients paced for reflex syncope. After 2018 ESC Guidelines for the diagnosis and management of syncope.8 CI-CSS, cardioinhibitory carotid sinus syndrome; ILR, implantable loop recorder; M, mixed; VASIS, vasovagal international study; VD, vasodepessor. This shows the currently anticipated rate of syncope recurrence in patients paced for reflex syncope. After 2018 ESC Guidelines for the diagnosis and management of syncope.8 CI-CSS, cardioinhibitory carotid sinus syndrome; ILR, implantable loop recorder; M, mixed; VASIS, vasovagal international study; VD, vasodepessor. The area of greatest difficulty for all in this field is when pacing is considered for reflex syncope. The Guidelines8 included current evidence concerning outcomes for pacing in reflex syncope (Table 1) where four categories are shown ranging from the gold standard of <5% in 2 years, comparable with pacing for atrioventricular block, to ineffective pacing where the dominant element in the syncope is vasodepressor (hypotensive susceptibility). Two to 3 years of follow-up is insufficient for pacemaker patients as they are justified in expecting their device to be effective in syncope prevention for 5–10 years and there are no studies reporting this duration of follow-up. Experience of the authors suggests that patients with reflex syncope maintain their risk of recurrence of syncope lifelong. Thus, at least for some and possibly for all, pacing for reflex syncope will never be perfect. With this new information on the subject showing an appreciable and important syncope recurrence rate,6 it is necessary to offer advice on how these patients should be managed. The first advice, as underlined by the authors themselves, is to make every effort to demonstrate a correlation between bradyarrhythmia and syncope before implanting a pacemaker. The implication of the above statement is a careful assessment of hypotensive susceptibility which is frequently present not only in patients with reflex syncope but also in those with suspected cardiac syncope. If hypotensive susceptibility is found, caution is advised in prescribing cardiac pacing and attention is required to counteract that susceptibility, where the most accessible and valuable step is to reduce hypotensive medications offered for treatment of hypertension and, possibly, also for prostate problems. The reduction or elimination of these medications will ameliorate their hypotension which is supported by the STOP-VD trial.9 A concurrent approach must be to confirm correct function of the pacing system, pacing failure is a rare cause of recurrent syncope occurring in 9% of those with recurrent syncope,6 and to consider reprogramming of the device.10 However, Guidelines have not addressed this aspect mainly on the basis of lack of proven efficacy. Finally, it is necessary to accept that no therapy is 100% effective. Syncope recurrence after pacing does not necessarily imply failure of pacing which may be expected to reduce the total burden of recurrence. So that a 20% recurrence rate can be considered acceptable provided that the severity of presenting symptoms justifies the initial implantation of a pacemaker. Conflict of interest: none declared. The opinions expressed in this article are not necessarily those of the Editors of Europace or of the European Society of Cardiology.
No takes yet. Share an insight, caveat, or question.
Sutton et al. (2020) conducted an editorial in Recurrent syncope in paced patients. Permanent pacing was evaluated. Permanent pacing for syncope prevention is associated with appreciable recurrence rates, highlighting the need to correlate bradyarrhythmia with syncope before device implantation.
Synapse has enriched 10 related papers. Consider them for comparative context: